CooperCompanies (Nasdaq: COO) is a global medical device company that develops and manufactures contact lenses through its subsidiary, CooperVision, and provides fertility and women’s healthcare solutions via CooperSurgical. The company reported its first quarter 2025 results, indicating a quarterly revenue of $965 million, which marks a 4% increase year-over-year and a 5% increase on an organic basis. This growth is primarily attributed to both CooperVision and CooperSurgical, which reported revenues of $646 million and $319 million, respectively.

CooperVision achieved organic revenue growth of 6% driven by particular strength in the Americas, where revenue rose by 8%. Additionally, the EMEA region saw a revenue increase of 6%, while Asia Pacific experienced a decline of 3%. Notably, the torics and multifocals categories grew by 10%. Overall, CooperSurgical’s revenue increased by 3% year-over-year, albeit it was slightly below initial expectations.

The consolidated gross margin improved to 68.7%, compared to 67.3% in the same quarter last year. The operating margin increased to 25.1%, reflecting efficiency improvements. Non-GAAP earnings per share were reported at $0.92, rising by 7.4% year-over-year. Free cash flow for the quarter was $101 million, supported by capital expenditures totaling $89 million, while net debt decreased to $2.44 billion.

For fiscal year 2025, the company expects it will generate revenues between $4.08 billion and $4.158 billion, up from prior projections of $3.94 billion to $4.02 billion. CooperVision’s revenue guidance remains unchanged, projected between $2.733 billion and $2.786 billion, while CooperSurgical maintains its guidance of $1.347 billion to $1.372 billion. Non-GAAP earnings per share guidance has been slightly increased to a range of $3.94 to $4.02 for the fiscal year, highlighting expected continued operational efficiency and solid margins.

The demand for CooperVision’s MyDay and the growth of its myopia management portfolio have been acknowledged, as the company seeks to expand its product offerings throughout various international markets. Despite significant growth, challenges in the Chinese market were noted, where revenue declined year-over-year.

In summary, CooperCompanies reported strong first-quarter results with a 4% increase in revenue and solid margin improvements, while it remains on track to achieve its full-year financial guidance amid operational successes in both CooperVision and CooperSurgical.